Pacira Pharmaceuticals Inc
Pacira Pharmaceuticals’ Top Line Continues to Expand
Pacira Pharmaceuticals (PCRX) is a specialty pharmaceutical company focused on bringing products to the market that are based on its proprietary DepoFoam technology.
How Is Insys Therapeutics Positioned in H2 2018?
Insys Therapeutics generated total revenues of $23.46 million in the second quarter of 2018 as compared to $42.58 million in the second quarter of 2017.
A Look at Johnson & Johnson’s Major Developments in 1Q17
As we discussed earlier, Johnson & Johnson’s 1Q17 segment-by-segment performance was positive across all of its segments. Now, let’s take a look at some of its major developments during 1Q17.
What Are IBB’s Holdings’ Moving Averages?
On May 27, 2016, 17% of the iShares Nasdaq Biotechnology ETF’s (IBB) stocks were trading above their 20-day moving averages.
Pacira’s Strong 3Q15 Results Helped the Pharma Subgroup
Pacira Pharmaceuticals (PCRX) rose 19.5% and closed at $49.12. Pacira had a weight of 0.25% in IBB’s portfolio. It was one of the top performers on October 27.